


Fact Sheet



2009 Q3 Update

Corporate Profile:

Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today – peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, flow diversion, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at www.ev3.net.



*Includes research collaboration revenue



**Excludes research collaboration revenue

Analyst Coverage[†]:

Exchange: NASDAQ
Ticker: EVVV

CHARLEY JONES
Barrington Research
cjones@brai.com

JOANNE WUENSCH
BMO Capital Markets
joanne.wuensch@bmo.com

JASON MILLS
Canaccord Adams
jason.mills@canaccordadams.com

CHRISTOPHER WARREN
Caris & Company
cwarren@cariscompany.com

MICHAEL WEINSTEIN
JPMorgan
mike.weinstein@jpmorgan.com

JOSH JENNINGS
Jefferies & Company, Inc.
joshjennings@jefferies.com

DAVID LEWIS
Morgan Stanley
david.r.lewis@morganstanley.com

JOSHUA ZABLE
Natixis Bleichroeder, Inc.
joshua.zable@blr.natixis.com

THOMAS GUNDERSON
Piper Jaffray
thomas.j.gunderson@pjc.com

LARRY NEIBOR
R.W. Baird
lneibor@rwbaird.com

TOM KOUCHOUKOS
Stifel Nicolaus & Company
kouchoukost@stifel.com

BETH SENKO
Williams Capital Group
senko@willcap.com

Investor Contact:

JULIE TRACY
Sr. Vice President
Chief Communications Officer
OFFICE 949-680-1375
MOBILE 209-613-6945
jtracy@ev3.net

ev3 Inc.
Corporate World Headquarters
9600 54th Avenue North
Plymouth, MN 55442-2111

[†] ev3 is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding ev3's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ev3 or its management. ev3 does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Recent Developments:

October 27, 2009

ev3 Inc. Reports 2009 Third Quarter Financial Results

Third Quarter Financial Results: ev3's net sales were \$112.8 million in the third quarter 2009 versus \$107.0 million in the same quarter of the prior year. Third quarter net product sales totaled \$112.8 million and increased 13% versus the third quarter 2008 net product sales and 15% on a constant currency basis. Third quarter of 2008 net sales included \$7.0 million of research collaboration revenues. ev3's GAAP net income for the third quarter of 2009 was \$6.7 million, or \$0.06 per diluted share. ev3's non-GAAP adjusted net income was \$19.4 million, or \$0.17 per diluted share, in the third quarter 2009 compared to \$3.9 million, or \$0.04 per diluted share, in the third quarter 2008. Total weighted average diluted shares outstanding used in the per share calculations were 112.3 million and 104.5 million for the third quarter of 2009 and 2008, respectively.

Outlook: ev3 expects fiscal year 2009 net sales to be in the range of \$446 to \$450 million. ev3 expects non-GAAP adjusted earnings per share to be in the range of \$0.58 to \$0.62 per diluted share based on approximately 109.1 million of outstanding shares. ev3's adjusted net earnings per share guidance excludes estimated amortization expense of \$25.0 million, non-cash stock-based compensation of approximately \$14.6 million, charges relating to the estimated change in fair value of the contingent consideration associated with the Chestnut acquisition of \$4.9 million, vacant leased facilities reserve expense of \$3.4 million, gain on divestiture of non-strategic investment assets of \$4.1 million, and a tax benefit of \$19.0 million resulting from the purchase accounting for the acquisition of Chestnut.

The company expects fourth quarter 2009 net sales to be in the range of \$124 to \$128 million and non-GAAP adjusted net earnings per share to be in the range of \$0.20 to \$0.24 per diluted share based on approximately 112.8 million of outstanding shares. ev3's non-GAAP adjusted net earnings per share exclude estimated amortization expense of approximately \$6.6 million, non-cash stock-based compensation of approximately \$3.6 million and charges relating to the estimated change in fair value of the contingent consideration associated with the Chestnut acquisition of \$2.4 million.

September 8, 2009

ev3 Inc. to present at the Morgan Stanley Global Healthcare Conference on September 14, 2009

ev3 presented at the Morgan Stanley Global Healthcare Conference on Monday, September 14, 2009. To access the webcast, go to <http://ir.ev3.net>.

September 3, 2009

ev3 Inc. to Present at the Thomas Weisel Partners Healthcare Conference on September 10, 2009

ev3 presented at the Thomas Weisel Partners Healthcare Conference on Thursday, September 10, 2009. To access the webcast, go to <http://ir.ev3.net>.

August 6, 2009

ev3 Inc. to Present at the 29th Annual Canaccord Adams Global Growth Conference on August 13, 2009

ev3 presented at the 29th Annual Canaccord Adams Global Growth Conference on Thursday, August 13, 2009. To access the webcast, go to <http://ir.ev3.net>.

July 29, 2009

ev3 Inc. to present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on August 5, 2009

ev3 presented at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5, 2009. To access the webcast, go to <http://ir.ev3.net>.

NEUROVASCULAR | PERIPHERAL VASCULAR

Access · Balloons · Carotid · Embolic Coils · Embolic Protection · Liquid Embolics · Plaque Excision · Procedural Support · Retrieval Devices · Stents

ev3 Corporate

World Headquarters
Peripheral Vascular
3033 Campus Drive
Plymouth, MN 55441
USA
PH +1 763 398 7000
FX +1 763 398 7001
Cust Srv +1 800 716 6700

www.ev3.net

ev3 Neurovascular

9775 Toledo Way
Irvine, CA 92618
USA
PH +1 949 837 3700
FX +1 949 837 2044

ev3 Europe

International Headquarters
106-108 rue La Boétie
75008 Paris
France
PH +33 156 88 59 10
FX +33 156 88 59 11

